Abstract
Tadalafil, developed jointly by ICOS Corporation and Eli Lilly and Company and approved by the FDA on November 21, 2003, under the trade name Cialis®, occupies a singular pharmacological position among approved PDE5 inhibitors. Its elimination half-life of approximately 17.5 hours — more than fourfold longer than that of sildenafil or vardenafil — results from a combination of structural factors that slow hepatic clearance, yielding a therapeutic window extending up to 36 hours post-administration. This review examines the structural basis of tadalafil's prolonged half-life, its ADME pharmacokinetic profile, clinical efficacy data from pivotal trials, the pharmacological rationale for once-daily low-dose dosing regimens, and its approved indication for pulmonary arterial hypertension (PAH) as Adcirca®. Tadalafil's remarkable selectivity for PDE5 over PDE11 — and its clinical implications — are also addressed.
1. Chemical Identity and Structural Basis of Extended Half-Life
The physicochemical properties of a drug molecule fundamentally determine its pharmacokinetic behavior. Tadalafil's extraordinary elimination half-life is not an incidental observation but rather a direct consequence of structural features that systematically reduce its rate of hepatic metabolism relative to the other approved PDE5 inhibitors.
Tadalafil (molecular formula: C₂₂H₁₉N₃O₄; molecular weight: 389.41 g/mol) is chemically distinct from both sildenafil and vardenafil in belonging to the carboline chemical class, rather than the pyrazolopyrimidinone scaffold shared by sildenafil and vardenafil. This structural divergence has profound pharmacokinetic consequences.
Specifically, tadalafil's beta-carboline ring system is sterically bulky and less amenable to rapid cytochrome P450-mediated oxidative metabolism. Furthermore, its relatively high molecular weight and specific lipophilicity characteristics result in a large volume of distribution (~63 L), contributing to the prolonged elimination phase. Tadalafil does not undergo significant N-demethylation to pharmacologically active metabolites — in contrast to sildenafil's active N-desmethyl metabolite — meaning that the parent compound itself drives the entirety of the extended pharmacodynamic effect.
Key Structural Features Contributing to Extended t½
Distinct chemical class from sildenafil/vardenafil; reduced susceptibility to CYP450 oxidation compared to pyrazolopyrimidinone core
Tadalafil is metabolized to inactive catechol glucuronide. No pharmacologically active metabolite prolongs or shortens the effective half-life
Tadalafil's intrinsic hepatic clearance via CYP3A4 is substantially lower than that of sildenafil, resulting in slower elimination from the systemic circulation
2. Mechanism of Action
In its fundamental pharmacodynamic mechanism, tadalafil operates through the same pathway as other PDE5 inhibitors: selective inhibition of PDE5 to prevent hydrolysis of cGMP, thereby amplifying the NO-mediated smooth muscle relaxation in the corpus cavernosum (see the Sildenafil page for a detailed description of the NO–cGMP–PDE5 pathway). However, several mechanistic distinctions between tadalafil and its congeners warrant specific discussion.
2.1 PDE5 Inhibitory Potency and Selectivity
Tadalafil demonstrates an IC₅₀ against PDE5 of approximately 0.94 nM — rendering it substantially more potent than sildenafil (~3.9 nM) at equivalent molar concentrations, though approximately 6-fold less potent than vardenafil (~0.14 nM). However, a critical distinction in tadalafil's selectivity profile concerns PDE11, a phosphodiesterase isoform expressed in testes, prostate, pituitary, and skeletal muscle tissue.
Of the three principal approved PDE5 inhibitors, tadalafil exhibits the lowest selectivity ratio for PDE5 versus PDE11 — with an IC₅₀ against PDE11 approximately 28-fold higher than its IC₅₀ against PDE5. While this remains a high degree of relative selectivity, it is notably lower than sildenafil's or vardenafil's PDE11 selectivity. Whether this PDE11 cross-reactivity translates to clinically meaningful effects — including reports of myalgia (back pain, limb pain) noted more frequently with tadalafil — remains an area of ongoing research interest.
Conversely, tadalafil demonstrates superior selectivity for PDE5 over PDE6 compared to sildenafil, with PDE6 inhibition occurring at concentrations more than 700-fold higher than those required for PDE5 inhibition. This accounts for the absence of visual disturbances (chromatopsia) as a recognized adverse effect of tadalafil — in stark contrast to sildenafil's notable ~3% incidence of such effects.
2.2 Hemodynamic Effects
Consistent with its mechanism, tadalafil produces modest reductions in systemic blood pressure (mean maximum: ~2–3 mmHg reduction in systolic, ~1–2 mmHg in diastolic) in healthy volunteers. These hemodynamic effects are clinically manageable in most patients but become significantly amplified with concomitant organic nitrate administration — the basis for the absolute contraindication shared by all PDE5 inhibitors.
3. Pharmacokinetics: The 17.5-Hour Half-Life
Tadalafil's pharmacokinetics have been extensively studied in healthy young and elderly male volunteers, patients with renal and hepatic impairment, and multiple special populations. The defining characteristic — the ~17.5-hour elimination half-life — requires detailed explication.
3.1 Absorption
Tadalafil is well-absorbed following oral administration. Peak plasma concentrations (Cmax) are achieved at a median Tmax of approximately 2 hours. A clinically important and practically significant pharmacokinetic characteristic is that tadalafil's absorption is not meaningfully affected by food intake — high-fat meals do not alter the rate or extent of tadalafil absorption (AUC and Cmax remain essentially unchanged). This food-independent absorption contrasts with sildenafil and vardenafil, both of which show delayed Tmax after high-fat meals, and provides tadalafil with a practical dosing flexibility advantage. The absolute oral bioavailability of tadalafil has not been reported in the prescribing information (it cannot be calculated without an intravenous formulation reference), but population modeling suggests values in the range of 80%.
3.2 Distribution
The mean volume of distribution of tadalafil is approximately 63 liters, suggesting distribution to tissues beyond the plasma compartment, though this is lower than sildenafil's ~105 L Vd. Tadalafil is approximately 94% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). Tadalafil is not significantly secreted into human semen. Less than 0.0005% of the administered dose appears in semen, rendering any pharmacological effect on sexual partners negligible.
3.3 Metabolism and the Basis of Extended Half-Life
Tadalafil is predominantly metabolized by CYP3A4 to a catechol metabolite, which is then rapidly converted to the methylcatechol and catechol sulfate glucuronide conjugates. The methylcatechol glucuronide is the predominant circulating metabolite in plasma. Critically, these metabolites have PDE5 inhibitory activity at least 13,000-fold less than tadalafil itself — they are pharmacologically inert from a clinical perspective.
The slow rate of CYP3A4-mediated metabolism of tadalafil — attributable to the structural characteristics of its beta-carboline scaffold — is the primary determinant of its prolonged half-life. Tadalafil's oral clearance is approximately 2.5 L/hour in healthy males, versus approximately 41 L/hour for sildenafil — a 16-fold difference in clearance that directly explains the proportionate difference in elimination half-life.
Pharmacokinetic Consequence of Extended Half-Life: Steady-State Accumulation
For once-daily 5 mg tadalafil dosing (approved for both ED and BPH), steady-state plasma concentrations are achieved within approximately 5 days, with an accumulation factor of approximately 1.6-fold relative to a single dose. At steady state, plasma concentrations remain at approximately 50% of Cmax for the entire 24-hour dosing interval — providing continuous, consistent PDE5 inhibitory coverage. This pharmacokinetic profile is the mechanistic basis for the once-daily dosing paradigm and represents a qualitatively different therapeutic model compared to the on-demand dosing of sildenafil or vardenafil.
3.4 Excretion and Special Populations
Tadalafil metabolites are excreted predominantly in feces (~61%) with a smaller fraction in urine (~36%), reflecting primary hepatic clearance with biliary excretion. In patients with mild to moderate hepatic impairment (Child-Pugh Class A or B), Cmax and AUC are not significantly altered, though caution is warranted. Severe hepatic impairment (Class C) has not been studied extensively, and tadalafil should be used with extreme caution in such patients. In patients with severe renal impairment (CrCl <30 mL/min), tadalafil exposure is increased approximately 2-fold, necessitating dose adjustment for once-daily regimens. Elderly patients (≥65 years) exhibit approximately 25% higher tadalafil AUC compared to younger patients, likely reflecting age-related reductions in CYP3A4 activity — modest changes that generally do not require routine dose adjustments.
4. Approved Dosing Regimens and Clinical Rationale
Tadalafil is uniquely approved in two distinct dosing paradigms for erectile dysfunction, both of which are direct pharmacokinetic consequences of its extended half-life.
On-Demand Dosing (10 mg / 20 mg)
The on-demand regimen — taking tadalafil 10 mg or 20 mg as-needed, approximately 30–45 minutes before anticipated sexual activity — exploits the drug's long half-life to provide a 36-hour therapeutic window. This extended window eliminates the need for precise temporal coordination between dosing and sexual activity that characterizes sildenafil and vardenafil use. Clinical trials with the 20 mg dose demonstrate response rates of approximately 81% in broadly inclusive ED populations.
The 36-hour window has been colloquially described as providing "a more natural approach" — because it de-medicalizes the timing of sexual activity. Pharmacologically, this window corresponds to approximately two elimination half-lives, during which plasma tadalafil concentrations remain at sufficient levels to provide clinically meaningful PDE5 inhibition.
Once-Daily Dosing (2.5 mg / 5 mg)
The once-daily 5 mg regimen — approved by the FDA in 2008 for ED and subsequently for benign prostatic hyperplasia (BPH) — represents a genuinely novel therapeutic concept in PDE5 inhibitor pharmacotherapy. The rationale is simple: because tadalafil's half-life of 17.5 hours approaches 24 hours, once-daily low-dose administration produces relatively stable steady-state plasma concentrations across the entire day, providing continuous background PDE5 inhibition.
Clinical trials of once-daily tadalafil 5 mg (including the SURE study and subsequent large-scale evaluations) demonstrate sustained improvements in IIEF scores comparable to those achieved with on-demand higher-dose regimens, with the added advantage of eliminating the need for pre-activity dosing planning. This regimen may also provide more consistent benefit for men whose erectile function involves spontaneous rather than planned sexual activity.
5. Pulmonary Arterial Hypertension: Adcirca® Indication
In 2009, the FDA approved tadalafil 40 mg once daily under the trade name Adcirca® for the treatment of pulmonary arterial hypertension (PAH) — a serious, progressive disease of the pulmonary vasculature characterized by elevated pulmonary vascular resistance and right ventricular strain. The pharmacological rationale is identical to the ED indication: PDE5 is highly expressed in pulmonary arterial smooth muscle, and tadalafil's inhibition of PDE5 in this tissue reduces pulmonary vascular resistance by elevating cGMP concentrations and promoting vasodilation.
The pivotal PHIRST-1 trial (Galiè N. et al., 2009; Circulation) demonstrated that tadalafil 40 mg once daily significantly improved the 6-minute walk distance (+33 meters vs. placebo), reduced the time to clinical worsening, and improved quality of life measures in patients with PAH (WHO functional class II or III). The once-daily high-dose regimen exploits tadalafil's extended half-life to provide continuous pulmonary vasodilation throughout the 24-hour dosing interval — a therapeutic requirement that could not be met with the shorter-acting sildenafil at a once-daily dose without risk of pharmacokinetically inadequate trough concentrations.
6. Safety Profile and Key Drug Interactions
The adverse effect profile of tadalafil is largely consistent with the PDE5 inhibitor class, with some important distinctions attributable to its unique selectivity characteristics and extended duration of action.
Adverse Effects (Comparative Notes)
- Headache~15%
- Dyspepsia~10%
- Back pain / myalgia~6% (unique to tadalafil)
- Nasal congestion~5%
- Flushing~5%
- Visual disturbances<1% (low PDE6 inhibition)
Back pain and myalgia, occurring in ~6% of patients and typically onset 12–24 hours post-dose, are hypothesized to relate to PDE11 inhibition in skeletal muscle and are generally self-limiting (resolving within 48 hours).
Critical Safety Information
- ABSOLUTE CONTRAINDICATION — Organic nitrates: As with all PDE5 inhibitors, co-administration with any form of organic nitrate is absolutely contraindicated due to potentially fatal hypotension.
- CYP3A4 inhibitors: Strong inhibitors (ritonavir, ketoconazole) markedly increase tadalafil AUC; a maximum of 10 mg every 72 hours is recommended with strong CYP3A4 inhibitors.
- Extended half-life and drug interaction duration: Due to the 17.5-hour half-life, clinically meaningful plasma concentrations persist for up to ~5 days (approximately 5 half-lives). Drug interactions persist substantially longer than with sildenafil or vardenafil.